Latest news and press releases
Mohit (Mo) Trikha is the CEO of Kivu Bioscience. He brings over 25 years of drug development expertise inoncology. He has been instrumental in advancing more than 40 programs from target identification to clinical trials in oncology.
Kivu Bioscience is naming Brunilda Shtylla Chief Business Officer, with Shtylla assuming the same role she held at Sutro Biopharma. Shtylla is tasked with leading corporate strategy, business development, and partnership initiatives as Kivu advances its antibody-drug conjugate (ADC) pipeline.
Kivu Bioscience Inc. has released new preclinical efficacy and safety data on KIVU-107, a novel PTK7-targeting antibody-drug conjugate with a DAR4 exatecan payload. KIVU-107 is designed to be highly stable in circulation with negligible free payload release, maximizing on-tumor activity while minimizing off-target toxicity.
“The Dutch biotech Synaffix has long been one of the top partners for biopharma companies working in antibody-drug conjugates. Now the company is spinning out …” Kyle LaHucik, Endpoints News
Sophia Randolph, M.D., Ph.D., Chief Medical Officer, Kivu Bioscience SAN MATEO, Calif.–(BUSINESS WIRE)–Kivu Bioscience, a biotechnology company advancing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced the appointment of Sophia Randolph, M.D., Ph.D., as Chief Medical Officer. As a medical oncologist, Dr. Randolph brings over 20 years of experience in oncology drug development advancing […]
KIVU-107 is the first PTK7-targeting ADC with a DAR4 exatecan payload, engineered for exceptional stability and highly selective on-tumor delivery. Preclinical data demonstrate deeper and durable anti-tumor activity across multiple xenograft models, with a wide therapeutic index and well-tolerated profile in repeat-dose GLP studies. Kivu to initiate a Phase 1 clinical study of KIVU-107 this […]
SAN FRANCISCO–(BUSINESS WIRE)–Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates, announced today a manufacturing partnership with Sterling Pharma Solutions, a global contract development and manufacturing organisation, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology antibody-drug conjugate (ADC) candidate, KIVU-107. Under the agreement, Sterling will manufacture cGMP clinical material for KIVU-107 […]
San Francisco, CA – October 28, 2024 – Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics, announced today the close of a $92 million Series A financing round led by Novo Holdings, with participation from Gimv, Red Tree Venture Capital, HealthCap as well as existing investors BioGeneration Ventures, M Ventures, […]